HCM
CLSD

Highbridge Capital Management’s Clearside Biomedical CLSD Stock Holding History

Highbridge Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,200
Closed -$164K – 1550
2017
Q2 		$164K Sell
1,200
-621
-34% -$74.6K ﹤0.01% 1137
2017
Q1 		$217K Buy
+1,821
New +$215K ﹤0.01% 1294

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Highbridge Capital Management's CLSD Position: Q3 2017 in Review

Highbridge Capital Management sold out of Clearside Biomedical (CLSD) in Q3 2017, closing a stake of 1,200 shares — an estimated $164K sold.

Highbridge Capital Management first reported a position in CLSD in Q1 2017 and held it in 2 quarters. The position peaked at $217K in Q1 2017. 50 funds tracked by Wall St. Rank hold CLSD as of Q3 2017.

  • Highbridge Capital Management reported no remaining Clearside Biomedical position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 1,200 Clearside Biomedical shares in Q3 2017, an estimated $164K.
  • Highbridge Capital Management first reported a position in Clearside Biomedical in Q1 2017 and held it in 2 quarters.
  • Highbridge Capital Management's Clearside Biomedical position peaked at $217K in Q1 2017.
  • 50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.